Heart Failure

Cardiovascular·MeSH: Heart Failure

Prevalence

1800.0 / 100K

Incidence

300.0 / 100K/yr

78 drugs in development·42 companies·75 clinical trials

Drug Pipeline by Phase

Approved(19)

Drug	Company
acetazolamide	Mylan II B.V. (MYL)
acetazolamide	ACHIEVE LIFE SCIENCES, INC. (ACHV)
acetazolamide	MANNKIND CORP (MNKD)
acetazolamide	Greenwich LifeSciences, Inc. (GLSI)
acetazolamide	Prestige Consumer Healthcare Inc. (PBH)
AMVUTTRA	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Bumetanide for Injection	CHINA PHARMA HOLDINGS, INC. (CPHI)
candesartan cilexetil	Aptinyx Inc. (APTX)
CardioMEMS® HF System	ABBOTT LABORATORIES (ABT)
carvedilol	Teva Pharmaceutical Industries Limited (TEVA)
fosinopril	Mylan II B.V. (MYL)
HeartMate® left ventricular assist device family	ABBOTT LABORATORIES (ABT)
inpefa	LEXICON PHARMACEUTICALS, INC. (LXRX)
Jardiance	ELI LILLY & Co (LLY)
Jardiance®	ELI LILLY & Co (LLY)
spironolactone	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
syncardia tah	Picard Medical Inc. (PMI)
valsartan	Mylan II B.V. (MYL)
Verquvo	Merck & Co., Inc. (MRK)

Phase 3(11)

Drug	Company
AZD5462	ASTRAZENECA PLC (AZN)
baxdrostat	ASTRAZENECA PLC (AZN)
CardiAMP®	BioCardia, Inc. (BCDA)
Finerenone	Crinetics Pharmaceuticals, Inc. (CRNX)
levosimendan	TENAX THERAPEUTICS, INC. (TENX)
myocell	U.S. Stem Cell, Inc. (USRM)
neucardin	SCICLONE PHARMACEUTICALS INC (SCLN)
Omecamtiv Mecarbil	CYTOKINETICS INC (CYTK)
rexlemestrocel-l	MESOBLAST LTD (MEOBF)
rexlemestrocel-l	Mesoblast Limited (MESO)
ziltivekimab	Novo Nordisk A/S (NVO)

Phase 2(18)

Drug	Company
[14c]azd5462	ASTRAZENECA PLC (AZN)
[14c]azd5462 solution for infusion	ASTRAZENECA PLC (AZN)
Activin ligand-trap biological therapy	Valneva SE (VALN)
Antiretroviral Therapy	Valneva SE (VALN)
apd418	ARENA PHARMACEUTICALS INC (ARNA)
azd5462 film-coated	ASTRAZENECA PLC (AZN)
cdr132l	Cardiol Therapeutics Inc. (CRDL)
cdr132l	Novo Nordisk A/S (NVO)
ck-4021586 (150 mg	CYTOKINETICS INC (CYTK)
danicamtiv	MyoKardia, Inc. (MYOK)
EDG-15400	Edgewise Therapeutics, Inc. (EWTX)
JTT-861 Capsules	Keros Therapeutics, Inc. (KROS)
pl-3994 aqueous intravenous solution dose ascention	PALATIN TECHNOLOGIES INC (PTN)
pl-3994 aqueous intravenous solution single dose	PALATIN TECHNOLOGIES INC (PTN)
RDX013	ARDELYX, INC. (ARDX)
tx45	Tectonic Therapeutic, Inc. (TECX)
Vericiguat suspension	Merck & Co., Inc. (MRK)
Vericiguat tablet	Merck & Co., Inc. (MRK)

Phase 1(5)

Drug	Company
cdr132l	Cardiol Therapeutics Inc. (CRDL)
CK-586	CYTOKINETICS INC (CYTK)
LY3971297	ELI LILLY & Co (LLY)
myocell sdf-1	U.S. Stem Cell, Inc. (USRM)
nnc0537-1482	Novo Nordisk A/S (NVO)

Preclinical(2)

Drug	Company
cnt-hf	Orchestra BioMed Holdings Inc. (OBIO)
emperor tah	Picard Medical Inc. (PMI)

Unknown(6)

Drug	Company
Allogeneic MSC therapy platform	BioCardia, Inc. (BCDA)
cardiamp system	BioCardia, Inc. (BCDA)
gencaro	Oruka Therapeutics, Inc. (ORKA)
Jardiance	CYTOKINETICS INC (CYTK)
Jardiance	ENANTA PHARMACEUTICALS INC (ENTA)
non-SGLT2 inhibitors	CYTOKINETICS INC (CYTK)

N/A(1)

Drug	Company
Calcium channel blocker	CYTOKINETICS INC (CYTK)

Phase 1/Phase 2(1)

Drug	Company
tn-301	Tenaya Therapeutics, Inc. (TNYA)

Phase 4(15)

Drug	Company
balcinrenone/dapagliflozin 15 mg/10 mg	ASTRAZENECA PLC (AZN)
balcinrenone/dapagliflozin 40 mg/10 mg	ASTRAZENECA PLC (AZN)
Baxdrostat and dapagliflozin	ASTRAZENECA PLC (AZN)
Beta Blocker	CYTOKINETICS INC (CYTK)
beta blockers	CYTOKINETICS INC (CYTK)
Beta-blocker treatment group	CYTOKINETICS INC (CYTK)
Beta-blockers	Valneva SE (VALN)
bms-986435	BRISTOL MYERS SQUIBB CO (BMY)
Dapagliflozin 10mg Tab	ENANTA PHARMACEUTICALS INC (ENTA)
Dapagliflozin 10Mg Tab	Travere Therapeutics, Inc. (TVTX)
empagliflozin	ENANTA PHARMACEUTICALS INC (ENTA)
ferinject	GH Research PLC (GHRS)
Hydralazine Isosorbide Dinitrate	ANI PHARMACEUTICALS INC (ANIP)
SGLT2i, beta blocker, ARNI, MRA, MTD	CYTOKINETICS INC (CYTK)
Vericiguat	CYTOKINETICS INC (CYTK)

BioSniper tracks 78 drugs in development for Heart Failure across 42 companies.

There are 75 clinical trials targeting Heart Failure tracked by BioSniper.

The estimated prevalence of Heart Failure is approximately 1800.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.